Literature DB >> 15794177

Botulinum toxin injections for children with excessive drooling.

Sharon Hassin-Baer1, Esther Scheuer, Aron S Buchman, Izhak Jacobson, Bruria Ben-Zeev.   

Abstract

The objective of this study was to evaluate the feasibility of ultrasonography-guided injections of botulinum toxin A into the parotid glands of children with severe drooling (sialorrhea). Excessive drooling is common in children with chronic neurologic disorders. Preliminary observations in adults suggest that injections of botulinum toxin A into the parotid glands can decrease drooling, but the optimal dose, sites of injection, and concomitant use of imaging during injections and its use for children have not been established. Ultrasonography was used to guide the injection of botulinum toxin (10-25 IU) into both parotid glands of nine children with excessive drooling. Subjective and objective measures of the severity of drooling were collected before and after botulinum toxin A injections. A booster injection was provided if the initial response was inadequate. Injections were well tolerated, and no adverse reactions were observed. Ultrasonography revealed that the parotid gland showed a variable depth, extent, and vascularization. Eight of nine patients needed a booster injection after 1 month. Objective measures of drooling severity were improved in seven of nine patients. However, subjective improvement was reported in only three of nine patients, and this improvement was functionally significant in only one patient. Although intraparotid injection of botulinum toxin A is safe and causes a reduction in saliva production in children, the doses used in this study did not result in functionally significant improvement. Higher doses of botulinum toxin A in the parotid glands or concomitant injections into the submandibular glands can increase the efficacy of these injections. Variability in size, depth, and vascular supply of the parotid gland suggests the importance of ultrasonography guidance for optimizing injections. These results underscore the need for further studies to establish the efficacy of this treatment in children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794177     DOI: 10.1177/08830738050200020701

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  5 in total

Review 1.  Evidence for the effectiveness of botulinum toxin for sialorrhoea.

Authors:  D D Truong; R Bhidayasiri
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

2.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

Review 3.  Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease.

Authors:  Marian L Evatt; K Ray Chaudhuri; Kelvin L Chou; Ester Cubo; Vanessa Hinson; Katie Kompoliti; Chengwu Yang; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2009-04-15       Impact factor: 10.338

4.  The Effectiveness of Botulinum Toxin Type A Injections in the Management of Sialorrhea.

Authors:  Özgür Sürmelioğlu; Muhammed Dağkıran; Ülkü Tuncer; Süleyman Özdemir; Özgür Tarkan; Fikret Çetik; Mete Kıroğlu
Journal:  Turk Arch Otorhinolaryngol       Date:  2018-06-01

5.  Botulinum toxin A inhibits salivary secretion of rabbit submandibular gland.

Authors:  Xiao-Feng Shan; Hui Xu; Zhi-Gang Cai; Li-Ling Wu; Guang-Yan Yu
Journal:  Int J Oral Sci       Date:  2013-10-25       Impact factor: 6.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.